MetaCap

Nephros Inc. (NEPH)

NASDAQ: NEPHHealth CareMedical/Dental InstrumentsUSD

2.61-0.23 (-8.10%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NEPH stock chart

Technical analysis

Key statistics

All statistics
Market cap
$28.37M
52-week range
2.61 – 6.42
Day range
2.61 – 2.85
Volume / Avg
50.23K / 48.33K
Beta
—

52-week range

$2.61$6.42

NEPH stock today

Nephros (NEPH) closed at $2.61 on Nov 20, down 8.10% (-$0.23), versus the S&P 500's 3.70% decline. Shares are 59.3% below their 52-week high of $6.42, set on Nov 26, 2025 and 0.0% above the 52-week low of $2.61, near the bottom of the past year's range. NEPH is down 46.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 46.4%.

Nephros trades at 15.4x its trailing twelve-month earnings per share of $0.17. Its forward P/E of 11.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Nephros

Company profile

Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water; reduce biofilm and scale build-up; and remove cysts, particulates, and lead from water systems.

Industry
Medical/Dental Instruments
CEO
Mr. Robert Banks
Headquarters
South Orange, NJ
Employees
36

Financial highlights

Full financials

In fiscal 2025, Nephros generated $18.8 million in revenue, up 32.7% from fiscal 2024. Net income was $1.2 million (+1513.5% year over year), for a net margin of 6.4% versus a median of -37.8% in the prior 5 years. Gross margin was 61.9% (up from 61.6%) and operating margin 6.1%.

Nephros annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$18.79M$14.16M$14.24M$9.97M$10.22M
Growth+32.67%-0.53%+42.74%-2.37%+19.34%
Net income$1.19M$74.00K$-1.57M$-7.11M$-3.87M
EPS (diluted)$0.11$0.01$-0.15$-0.73$-0.41

Analyst forecast

Forecast

Consensus (3 analysts)

none

Avg. price target

$6.25+139.46%

  • Strong buy 1
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $4.75High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.05 vs $0.02
Surprise
+150.00%

NEPH news

All NEPH news

Nephros peers

Health Care sector
NEPH peer companies
CompanyPrice% ChgMarket capCompare
NSPRInspireMD Inc.0.54-12.97%$29.23Mvs NEPH
XTNTXtant Medical Holdings Inc.0.21-2.82%$29.49Mvs NEPH
TELATELA Bio Inc.0.6885-5.27%$31.11Mvs NEPH
MDAISpectral AI Inc. Class A1.04-20.61%$33.47Mvs NEPH
PLRZPolyrizon Ltd.9.31-8.42%$22.61Mvs NEPH
DAVIDavion Healthcare Plc0.9001-9.99%$22.50Mvs NEPH
SRTSSensus Healthcare Inc.2.26-4.24%$37.20Mvs NEPH
PMIPicard Medical Inc.6.79+7.78%$18.07Mvs NEPH

Indexes, lists and sector

Nephros stock FAQ

What is Nephros's stock price today?

NEPH last traded at $2.61 as of Nov 20, 4:00 PM EST, down 8.10% on the day. Prices are delayed at least 15 minutes.

Does Nephros pay a dividend?

No. Nephros does not currently pay a regular cash dividend.

What is NEPH's P/E ratio?

NEPH trades at a trailing P/E ratio of 15.35 and a forward P/E of 11.86.

Who is Nephros's CEO?

Mr. Robert Banks is the chief executive officer of Nephros Inc., which has about 36 employees.

Has NEPH ever split its stock?

Yes. The most recent NEPH stock split was a 1-for-9 split on Jul 10, 2019, one of 2 splits on record.

What is the NEPH 52-week high?

The 52-week high for NEPH is $6.42 and the 52-week low is $2.61. The stock is currently 59.3% below its high.

Compare NEPH